Understanding the Role of Toll-like Receptors in Lung Cancer Immunity and Immunotherapy

Overview

Journal Front Immunol

Specialty Allergy & Immunology

Date 2022 Nov 17

PMID 36389785

Authors

Bettina Hoden

David DeRubeis

Margarita Martinez-Moczygemba

Kenneth S Ramos

Dekai Zhang

Affiliations

Soon will be listed here.

Abstract

Lung cancer is currently the leading cause of cancer-related deaths worldwide. Significant improvements in lung cancer therapeutics have relied on a better understanding of lung cancer immunity and the development of novel immunotherapies, as best exemplified by the introduction of PD-1/PD-L1-based therapies. However, this improvement is limited to lung cancer patients who respond to anti-PD-1 immunotherapy. Further improvements in immunotherapy may benefit from a better understanding of innate immune response mechanisms in the lung. Toll-like receptors (TLRs) are a key component of the innate immune response and mediate the early recognition of pathogen-associated molecular patterns (PAMPs) and damage-associated molecular patterns (DAMPs). TLR signaling modulates the tumor microenvironment from "cold" to "hot" leading to immune sensitization of tumor cells to treatments and improved patient prognosis. In addition, TLR signaling activates the adaptive immune response to improve the response to cancer immunotherapy through the regulation of anti-tumor T cell activity. This review will highlight recent progress in our understanding of the role of TLRs in lung cancer immunity and immunotherapy.

Citing Articles

Toll-Like Receptor 4 and 8 are Overexpressed in Lung Biopsies of Human Non-small Cell Lung Carcinoma.

Ceccarelli S, Pasqua Marzolesi V, Vannucci J, Bellezza G, Floridi C, Nocentini G Lung. 2025; 203(1):38.

PMID: 40025339 PMC: 11872755. DOI: 10.1007/s00408-025-00793-8.

Network pharmacology and molecular docking reveal the mechanism of action of Bergapten against non‑small cell lung cancer.

Chen Y, Fu Y, Zou H, Wang P, Xu Y, Xie Q Oncol Lett. 2024; 29(2):87.

PMID: 39677411 PMC: 11638938. DOI: 10.3892/ol.2024.14833.

Influence of Donor-Specific Characteristics on Cytokine Responses in H3N2 Influenza A Virus Infection: New Insights from an Ex Vivo Model.

Huang C, Hsieh M, Wu Y, Huang P, Lin Y, Tsao K Int J Mol Sci. 2024; 25(20).

PMID: 39456722 PMC: 11507259. DOI: 10.3390/ijms252010941.

Toll-like Receptors: Key Players in Squamous Cell Carcinoma Progression.

Smok-Kalwat J, Mertowska P, Mertowski S, Gozdz S, Grywalska E J Clin Med. 2024; 13(15).

PMID: 39124797 PMC: 11313009. DOI: 10.3390/jcm13154531.

Premalignant Progression in the Lung: Knowledge Gaps and Novel Opportunities for Interception of Non-Small Cell Lung Cancer. An Official American Thoracic Society Research Statement.

Moghaddam S, Savai R, Salehi-Rad R, Sengupta S, Kammer M, Massion P Am J Respir Crit Care Med. 2024; 210(5):548-571.

PMID: 39115548 PMC: 11389570. DOI: 10.1164/rccm.202406-1168ST.

References

Kim H, Park B, Kim J, Kim S, Lee J, Oh S . Crystal structure of the TLR4-MD-2 complex with bound endotoxin antagonist Eritoran. Cell. 2007; 130(5):906-17. DOI: 10.1016/j.cell.2007.08.002. View

Liu Y, Gu Y, Han Y, Zhang Q, Jiang Z, Zhang X . Tumor Exosomal RNAs Promote Lung Pre-metastatic Niche Formation by Activating Alveolar Epithelial TLR3 to Recruit Neutrophils. Cancer Cell. 2016; 30(2):243-256. DOI: 10.1016/j.ccell.2016.06.021. View

Piggott D, Eisenbarth S, Xu L, Constant S, Huleatt J, Herrick C . MyD88-dependent induction of allergic Th2 responses to intranasal antigen. J Clin Invest. 2005; 115(2):459-67. PMC: 544038. DOI: 10.1172/JCI22462. View

He W, Liu Q, Wang L, Chen W, Li N, Cao X . TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance. Mol Immunol. 2007; 44(11):2850-9. DOI: 10.1016/j.molimm.2007.01.022. View

Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N . In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother. 2010; 59(12):1839-49. PMC: 2945474. DOI: 10.1007/s00262-010-0909-y. View

Kauppila J, Mattila A, Karttunen T, Salo T . Toll-like receptor 5 (TLR5) expression is a novel predictive marker for recurrence and survival in squamous cell carcinoma of the tongue. Br J Cancer. 2013; 108(3):638-43. PMC: 3593548. DOI: 10.1038/bjc.2012.589. View

Lemjabbar-Alaoui H, Hassan O, Yang Y, Buchanan P . Lung cancer: Biology and treatment options. Biochim Biophys Acta. 2015; 1856(2):189-210. PMC: 4663145. DOI: 10.1016/j.bbcan.2015.08.002. View

Wculek S, Cueto F, Mujal A, Melero I, Krummel M, Sancho D . Dendritic cells in cancer immunology and immunotherapy. Nat Rev Immunol. 2019; 20(1):7-24. DOI: 10.1038/s41577-019-0210-z. View

Kirk G, Merlo C, O Driscoll P, Mehta S, Galai N, Vlahov D . HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis. 2007; 45(1):103-10. PMC: 4078722. DOI: 10.1086/518606. View

10.

Georg P, Sander L . Innate sensors that regulate vaccine responses. Curr Opin Immunol. 2019; 59:31-41. DOI: 10.1016/j.coi.2019.02.006. View

11.

Zhou H, Jiang M, Yuan H, Ni W, Tai G . Dual roles of myeloid-derived suppressor cells induced by Toll-like receptor signaling in cancer. Oncol Lett. 2021; 21(2):149. PMC: 7798029. DOI: 10.3892/ol.2020.12410. View

12.

Vidya M, Kumar V, Sejian V, Bagath M, Krishnan G, Bhatta R . Toll-like receptors: Significance, ligands, signaling pathways, and functions in mammals. Int Rev Immunol. 2017; 37(1):20-36. DOI: 10.1080/08830185.2017.1380200. View

13.

Jungnickel C, Schmidt L, Bittigkoffer L, Wolf L, Wolf A, Ritzmann F . IL-17C mediates the recruitment of tumor-associated neutrophils and lung tumor growth. Oncogene. 2017; 36(29):4182-4190. DOI: 10.1038/onc.2017.28. View

14.

Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y . TLR9 signaling promotes tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 2009; 15(4):623-30. DOI: 10.1007/s12253-009-9162-0. View

15.

Sigel K, Wisnivesky J, Gordon K, Dubrow R, Justice A, Brown S . HIV as an independent risk factor for incident lung cancer. AIDS. 2012; 26(8):1017-25. PMC: 3580210. DOI: 10.1097/QAD.0b013e328352d1ad. View

16.

Mokhtari Y, Pourbagheri-Sigaroodi A, Zafari P, Bagheri N, Ghaffari S, Bashash D . Toll-like receptors (TLRs): An old family of immune receptors with a new face in cancer pathogenesis. J Cell Mol Med. 2020; 25(2):639-651. PMC: 7812258. DOI: 10.1111/jcmm.16214. View

17.

Lechmann M, Zinser E, Golka A, Steinkasserer A . Role of CD83 in the immunomodulation of dendritic cells. Int Arch Allergy Immunol. 2002; 129(2):113-8. DOI: 10.1159/000065883. View

18.

Tavora B, Mederer T, Wessel K, Ruffing S, Sadjadi M, Missmahl M . Tumoural activation of TLR3-SLIT2 axis in endothelium drives metastasis. Nature. 2020; 586(7828):299-304. PMC: 8088828. DOI: 10.1038/s41586-020-2774-y. View

19.

Kumar H, Kawai T, Akira S . Pathogen recognition by the innate immune system. Int Rev Immunol. 2011; 30(1):16-34. DOI: 10.3109/08830185.2010.529976. View

20.

Silverberg M, Lau B, Achenbach C, Jing Y, Althoff K, DSouza G . Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study. Ann Intern Med. 2015; 163(7):507-18. PMC: 4711936. DOI: 10.7326/M14-2768. View